This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Teva Reveals Tardive Dyskinesia...
Tech medical study results

Teva Reveals Tardive Dyskinesia Diagnostic Gaps

Analysis based on 7 articles · First reported May 18, 2026 · Last updated May 18, 2026

Sentiment
20
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The announcement of new data by Sun Pharma regarding diagnostic gaps in tardive dyskinesia could positively impact its stock price by demonstrating its commitment to research and potential for future product development in this area. Improved diagnosis rates could lead to increased demand for treatments, benefiting Sun Pharma's market position.

Pharmaceuticals Healthcare
Event Summary

Sun Pharma announced new data from its IMPACT-TD Registry at the 2026 American Psychological Association Annual Meeting. The study highlights a significant gap in diagnosing tardive dyskinesia (TD) in patients with underlying mood disorders, particularly among young adults (18-29), where only 23% received a formal diagnosis despite 85% experiencing moderate to severe impact. The IMPACT-TD Registry is a 3-year, prospective, non-interventional, Phase 4 study examining TD progression and its impact on patients' lives. The findings indicate that TD causes a profound, multidimensional burden across all age groups, affecting daily living, psychological well-being, and social interaction. Sun Pharma is committed to addressing these diagnostic gaps to improve outcomes for patients living with TD.

Entities Involved
per
Verena Ramirez Campos
Verena Ramirez Campos, Vice President U.S. Medical Affairs and Global Innovative Strategy at Sun Pharma, commented on the IMPACT-TD Registry data, emphasizing the company's commitment to addressing diagnostic gaps in tardive dyskinesia.
Importance 40.0 Sentiment 0.0
per
Richard Jackson
Richard Jackson, an Assistant Clinical Adjunct Professor at the University of Michigan School of Medicine's Department of Psychiatry and IMPACT-TD principal investigator, provided insights into the study's importance for understanding tardive dyskinesia's impact on patients with mood disorders.
Importance 40.0 Sentiment 0.0
ngo
American Psychological Association
The American Psychological Association hosted its Annual Meeting where Sun Pharma presented the new data from the IMPACT-TD Registry.
Importance 20.0 Sentiment 0.0
stock
Sun Pharma
Importance 0 Sentiment 0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.